Skip to main content

Market Overview

BioCryst Gains After FDA Nod For Expanded Use of RAPIVAB

  • BioCryst Pharmaceuticals Inc (NASDAQ: BCRX) shares jump after the FDA approved supplemental marketing application seeking approval for RAPIVAB (peramivir injection) to treat acute uncomplicated influenza to include patients six months and older who have been symptomatic for no more than two days.
  • Before this approval, RAPIVAB had been indicated for patients two years and older.
  • BCRX shares gained 7.03% at $11.27 pre-market on the last check Wednesday.

Related Articles (BCRX)

View Comments and Join the Discussion!

Posted-In: influenzaBiotech News Small Cap FDA General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at